(ii) The development of ADCs against BC has primarily focused on established targets, such as HER2 and trophoblast antigen 2 (Trop-2), but potential targets like CD44, folate receptor alpha, and other tumor-associated antigens that are overexpressed in specific breast cancer populations should also be focused upon. Here, TACSTD2 is linked to neoplasm.